ELUTIA INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.83 USD | -1.03% |
|
+12.32% | +77.31% |
| May. 09 | Elutia Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| May. 09 | Earnings Flash (ELUT) ELUTIA Posts Q1 Revenue $6.7M, vs. Street Est of $6.1M | MT |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- The company has a poor ESG score according to Refinitiv, which ranks companies by sector.
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- Low profitability weakens the company.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last few months, analysts have been revising downwards their earnings forecast.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +77.31% | 93.26M | D | ||
| +0.85% | 92.38B | A- | ||
| -3.03% | 37.9B | A- | ||
| -10.46% | 33.73B | B- | ||
| +74.71% | 27.98B | A | ||
| -13.39% | 15.86B | C | ||
| -1.08% | 13.97B | B- | ||
| -11.15% | 11.67B | D+ | ||
| +169.04% | 10.17B | D | ||
| -50.19% | 10.04B | B |
Investor Rating
Trading Rating
-
ESG Refinitiv
Financials
Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
-
Valuation
P/E ratio
-
EV / Sales
-
Price to Book
-
Price to Free Cash Flow
-
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- ELUT Stock
- Ratings Elutia Inc.
